A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

Shawn Johnson shares daughter Drew Hazel, 4, and sons Jett James, 2, and Barrett 'Bear' Madison, 10 months, with her husband ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...

AUSTIN (KXAN) — In 2023, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...